Effects of metformin on endometrial cancer cell growth in vivo: A preoperative prospective trial

BACKGROUND Metformin, an antidiabetic drug, decreases the incidence of various cancers in diabetic patients. Metformin‐induced inhibition of cancer cell proliferation has been confirmed in vitro but not in humans. Because endometrial cancer is associated with insulin resistance, the authors investig...

Full description

Saved in:
Bibliographic Details
Published in:Cancer 2014-10, Vol.120 (19), p.2986-2995
Main Authors: Mitsuhashi, Akira, Kiyokawa, Takako, Sato, Yasunori, Shozu, Makio
Format: Article
Language:English
Subjects:
Adult
Aged
AMP-Activated Protein Kinases - metabolism
Antigens, Neoplasm - metabolism
Antineoplastic Agents - therapeutic use
Blotting, Western
Carcinoma, Endometrioid - drug therapy
Carcinoma, Endometrioid - metabolism
Carcinoma, Endometrioid - pathology
Carcinoma, Endometrioid - surgery
Cell Line, Tumor
Cell Proliferation - drug effects
Chemotherapy, Adjuvant
DNA Topoisomerases, Type II - metabolism
DNA-Binding Proteins - metabolism
endometrial cancer
Endometrial Neoplasms - drug therapy
Endometrial Neoplasms - pathology
Endometrial Neoplasms - surgery
Female
growth inhibition
Humans
Hypoglycemic Agents - therapeutic use
Immunohistochemistry
in vivo
insulin resistance
Ki-67 Antigen - metabolism
MAP Kinase Signaling System
metformin
Metformin - therapeutic use
Middle Aged
Mitogen-Activated Protein Kinase 1 - metabolism
Mitogen-Activated Protein Kinase Kinases - metabolism
Neoadjuvant Therapy - methods
Neoplasm Grading
Neoplasm Staging
Proliferating Cell Nuclear Antigen - metabolism
Prospective Studies
Ribosomal Protein S6 - metabolism
TOR Serine-Threonine Kinases - metabolism
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:BACKGROUND Metformin, an antidiabetic drug, decreases the incidence of various cancers in diabetic patients. Metformin‐induced inhibition of cancer cell proliferation has been confirmed in vitro but not in humans. Because endometrial cancer is associated with insulin resistance, the authors investigated whether a diabetes‐therapeutic metformin dose inhibits cancer cell growth in patients with endometrial cancer. METHODS A dose of metaformin was administered (1500‐2250 mg/day) to 31 patients with endometrial cancer preoperatively for 4 to 6 weeks. Cell proliferation was assessed in patient tissues using immunohistochemical and Western blot analyses and DNA synthesis was measured in serum using a thymidine uptake assay. All statistical tests were 2‐sided. P values of 
ISSN:0008-543X
1097-0142
DOI:10.1002/cncr.28853